Patents
Literature
2 results about "Reserpine" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Reserpine is a drug that is used for the treatment of high blood pressure, usually in combination with a thiazide diuretic or vasodilator. Large clinical trials have shown that combined treatment with reserpine plus a thiazide diuretic reduces mortality of people with hypertension. Although the use of reserpine as a solo drug has declined since it was first approved by the FDA in 1955, a review recommends use of reserpine and a thiazide diuretic or vasodilator in patients who do not achieve adequate lowering of blood pressure with first-line drug treatment alone. The reserpine-hydrochlorothiazide combo pill was the 17th most commonly prescribed of the 43 combination antihypertensive pills available In 2012.
Application of reserpine in construction of animal model with normal high and low density lipoprotein and triglyceride values
The invention belongs to the technical field of experimental animals, and particularly relates to application of reserpine in construction of animal models with normal high and low density lipoprotein and triglyceride values. The animal model construction method is minimally invasive, low in cost and good in reproducibility, has remarkable western medicine clinical biochemical index characteristics and a clear action mechanism, and can successfully and repeatedly establish an animal model with high and low density lipoprotein and normal triglyceride values. Conditions are created for clinical research on pathogenesis of related diseases, diagnosis and treatment of related diseases and screening, research and treatment of related disease mechanisms and drugs thereof, and good application prospects are achieved.
Owner:JIANGHAN UNIVERSITY
Hybridoma cell strain secreting anti-reserpine monoclonal antibody and its application
The present application relates to a hybridoma cell strain secreting anti-reserpine monoclonal antibody and its application, and belongs to the technical field of drug safety immune detection. The hybridoma cell strain secreting anti-monoclonal antibody has been preserved in the China General Microbiological Culture Collection Center on April 17, 2025, with a preservation number of CGMCC No. 46508, a preservation address of No. 3, Xibaixili, Chaoyang District, Beijing, and a classification designation of monoclonal cell strain. The reserpine monoclonal antibody cell strain obtained by the present application can be used for reserpine analysis and detection in drugs and food, has good detection sensitivity (IC 50 value of 0.579 ng / mL) and specificity (cross rate of less than 1% for related structural analogues), can realize the detection of reserpine in drugs, can assist clinical diagnosis, and has practical application value.
Owner:JIANGNAN UNIV